With further analysis of NTG-induced migraine mice on NT-3 immunoreactivity, no significant difference was found between NTG-injected mice and mice treated with 10 mg/kg of SCFAs (Figure 6L,O for SP and SB, respectively). Here, NTF3 is linked to migraine disorder.